Events

Join us for an engaging sushi lunch seminar to discover how Standard BioTools’ portfolio, including the XT Pro CyTOF and Hyperion XTi Imaging Mass Cytometry (IMC), can be combined with spatial transcriptomics to unlock new dimensions of biological insight. In this session, you’ll learn how same-slide spatial multi-omics empowers deeper understanding of tissue biology, enabling precise mapping of tumor microenvironments and immune landscapes. Agenda: • Meet the Team – Connect with Standard BioTools and discover the CyTOF and IMC portfolio • Application Highlights – See how CyTOF drives deeper insights in cancer research and how IMC reveals clinically relevant protein expression • Spatial Multi-Omics – Learn how IMC can be combined for same-slide multiomics, unlocking powerful new insights into tumor biology, immune landscapes, and drug development

Englander Institute for Precision Medicine Seminar Series "Multi-omic and Functional Landscapes of Melanoma Converge on Clinically Actionable Features" Presented by Mitch Levesque, PhD Full Professor of Dermato-Oncology, University of Zurich, Switzerland Co-Head of Research, Department of Dermatology, University Hospital Zurich, Switzerland Bio: Professor Mitch Levesque is Full Professor of Dermato-Oncology at the University of Zurich, Switzerland and Co-Head of Research in the Department of Dermatology at the University Hospital Zurich. His group focuses on understanding how tumor heterogeneity and the immune microenvironment influence treatment resistance and response in melanoma. As Head of the Skin Cancer Biobank, Prof. Levesque leads one of Europe’s most comprehensive melanoma collections, integrating clinical, molecular, and functional data to accelerate biomarker discovery and precision oncology. His research has contributed to identifying molecular predictors of immunotherapy response and mechanisms of adaptive resistance to targeted therapies, with findings published in Nature Medicine, Cancer Cell, and Cell. A founding member of the Skintegrity.CH consortium and the Tumor Profiler program, he promotes close collaboration between clinicians, pathologists, and data scientists to bring high-dimensional analyses into patient care. He is also co-founder of Oncobit AG, a spin-off translating blood-based biomarker technologies for real-time monitoring of cancer therapy.

Englander Institute for Precision Medicine Seminar Series "The Highs and Lows (-plex) of Spatial Biology in Autoimmune Research" Presented by M. Caleb Marlin, PhD Senior Scientist and Imaging Project Manager, Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation Description: Spatial biology is a growing field of impactful technologies and analysis tools that allow researchers to understand the cellular and molecular makeup of a given tissue in its native spatial context. This understanding provides a unique opportunity to answer questions that no other field of study can investigate. There exists a wide range of imaging technologies that identify different numbers of markers and/or different analytes altogether. Leveraging these seemingly disparate technologies together provide us with a more holistic understanding of the tissue in clinically meaningful ways. Here, Dr. Marlin will discuss how the Guthridge/James lab at the Oklahoma Medical Research Foundation is working with both high- and low-plex datasets to better understand afflicted tissues in autoimmunity. Bio: Dr. Caleb Marlin is a Senior Staff Scientist and Imaging Project Manager in the labs of Drs. Judith James and Joel Guthridge in the Arthritis and Clinical Immunology Research Program at the Oklahoma Medical Research Foundation. Their research focuses predominantly on understanding the underlying mechanisms contributing to autoimmune diseases like Lupus, Sjogren’s Disease, Rheumatoid Arthritis, and Multiple Sclerosis. With deep-phenotyping capabilities and single-cell technologies, in combination with their biorepository and local clinics, their group combines large informatics approaches with clinical data to better understand these diseases and better treat patients afflicted with autoimmunity.